Quantum BioPharma Ltd. - רווח למניה לשנה מתגלגלת QNTM

Quantum BioPharma Ltd (QNTM) is currently shifting its strategic direction, focusing on functional beverages and psychedelic research. The business relies on a multidisciplinary network of therapeutic solutions that integrate research centers with B2B raw material supplies. The company's innovations are based on the creation of nanoparticles for targeted action on pathologies. This EPS (TTM) chart demonstrates a current figure of 58.30, confirming the growth dynamics of this biopharmaceutical project.

To assess the credit quality of Quantum BioPharma Ltd (QNTM), the analyst utilizes a rolling YoY earnings per share (EPS) metric, which measures annual net income dynamics through a daily revaluation of operating revenues amid high borrowing costs. In the context of a shifting business model and R&D expenditures, this chart reveals the risk of cash flow gaps, warning that even peak values do not guarantee protection against market shocks.